CVS Health Corporation $CVS Position Cut by Swiss National Bank

Swiss National Bank trimmed its holdings in CVS Health Corporation (NYSE:CVS) by 4.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,475,660 shares of the pharmacy operator’s stock after selling 170,900 shares during the quarter. Swiss National Bank’s holdings in CVS Health were worth $275,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC boosted its stake in shares of CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after acquiring an additional 79,340 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of CVS Health by 50.3% during the 3rd quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after acquiring an additional 28,953 shares in the last quarter. Assetmark Inc. boosted its stake in shares of CVS Health by 12.5% during the 3rd quarter. Assetmark Inc. now owns 678,558 shares of the pharmacy operator’s stock worth $51,156,000 after acquiring an additional 75,603 shares in the last quarter. Hamlin Capital Management LLC bought a new stake in shares of CVS Health during the 4th quarter worth $160,844,000. Finally, Cresset Asset Management LLC boosted its stake in shares of CVS Health by 56.8% during the 3rd quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock worth $2,675,000 after acquiring an additional 12,849 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Price Performance

CVS opened at $100.38 on Friday. The stock has a fifty day moving average of $86.32 and a 200-day moving average of $80.63. The firm has a market capitalization of $128.08 billion, a P/E ratio of 44.22, a PEG ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $100.55. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by corporate insiders.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health said it is using Fluency’s enterprise AI platform to move autonomous agents from pilot projects into production, a sign it is working to cut administrative costs and improve workflow efficiency across the business. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Positive Sentiment: Aetna launched “Mental Health on Demand,” which gives members real-time access to care and ongoing support; the company highlighted very fast clinician connection times, underscoring stronger service delivery and potentially better member engagement. Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support
• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight-loss medications, a move that may support affordability for members while strengthening the company’s position in a fast-growing and closely watched drug category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

Analysts Set New Price Targets

CVS has been the subject of several research reports. Wells Fargo & Company raised their price objective on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Mizuho raised their price objective on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday. Morgan Stanley increased their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Finally, Truist Financial increased their target price on CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a report on Monday, June 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.